Modality
Small Molecule
MOA
Anti-Aβ
Target
PARP
Pathway
RNA Splicing
MDS
Development Pipeline
Preclinical
Aug 2022
→ Nov 2031
PreclinicalCurrent
NCT03318096
101 pts·MDS
2022-08→2031-11·Active
101 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-11-045.6y awayInterim· MDS
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Preclinical
Active
Catalysts
Interim
2031-11-04 · 5.6y away
MDS
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03318096 | Preclinical | MDS | Active | 101 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| LLY-8369 | Eli Lilly | Approved | Menin | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| CRS-337 | CRISPR Therapeutics | Phase 2/3 | PARP | |
| RLA-6817 | Relay Therapeutics | Phase 3 | TIGIT |